A clinical-stage biotechnology company developing immune-modulating therapies aimed at treating autoimmune and inflammatory diseases. Its lead program, MIS416, has been studied as a potential treatment for progressive multiple sclerosis by targeting innate immune pathways. Investors have followed th...
No congressional trades have been disclosed for Innate Immunotherapeutics Ltd (IILTF) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
No congressional trades found for this stock.